Innovative Partnership Nominated for Citeline Award

CISCRP proudly participated in a 2019 collaboration with Biogen, the National Minority Quality Forum (NMQF), Tufts Center for the Study of Drug Development (CSDD), Langland, H.E.A.L. and the FDA’s Office of Minority Health and Health Equity to engage directly with the general public through grass-roots outreach campaigns and events; to listen to their level of understanding, awareness, and concerns through digital channels, in-person meetings and interviews; and to provide resources to support education about clinical research participation. These efforts proved valuable and impactful, receiving endorsement to continue to build and expand these efforts in 2020 and beyond. This innovative 2019 project has recently been nominated as a finalist in the 2020 Citeline Awards for Medidata Clinical Partnership of the Year.

The team worked to better understand the challenges and barriers encountered by African American and Hispanic/Latinx communities in the US regarding awareness, access to clinical research participation, and health care provider involvement in evaluating research opportunities. 

As a part of this large engagement campaign, Tufts CSDD conducted in-depth interviews among minority physicians, investigators and nurses to explore barriers and challenges to clinical trial access and referral, as well as high incidence of minority investigator drop-out rates. An online social listening campaign was launched to follow conversations and sentiments around clinical trials among African Americans and Hispanic/Latinx communities. CISCRP and the NMQF organized public-facing programs that offered free health screenings and educational sessions. The FDA participated in Biogen’s Patient Engagement Day and spoke to the importance of engaging underrepresented minorities in clinical trials.

Insights obtained from these conversations will assist the team in enhancing current structures and implementing new efforts to increase access to clinical trial sites and site participation in clinical trials. Feedback provided by online social listening and healthcare providers reinforced existing barriers to clinical research participation for members of diverse communities.

“While the public continues to acknowledge the importance of clinical research in identifying new medicines, general awareness and participation in clinical research studies remain low for a variety of reasons, and minority populations continue to be underrepresented in clinical trials,” said Ellyn Getz, Associate Director, Development and Community Engagement for CISCRP. “Many learnings from this year-long program will be applied in 2020 to patient engagement strategies, protocol entry criteria, site selection, and patient outreach.”

In 2019, approximately 2,000 people attended NMFQ’s community health events and CISCRP’s AWARE for All programs and learned about clinical trial participation. Over 500 event attendees surveyed indicated that they are somewhat or very interested and willing to participate in a clinical trial and are eager to participate if invited by their health care provider. This indicates an opportunity to further engage, educate, and connect underrepresented patients with clinical trial site teams.

This innovative collaboration has built a strong foundation for continued grass-roots outreach efforts. Biogen is supporting the AWARE for All: Clinical Research Education event series over the next five years as a member of CISCRP’s AWARE Industry Consortium. The consortium addresses the critical need to improve patient diversity in clinical trials.

For more information, please contact Joan Chambers, CISCRP’s Senior Director, Marketing and Outreach, at or Ellyn Getz, Associate Director, Development & Community Engagement, at

New Consortium Launched In Partnership with CISCRP to Improve National Clinical Research Literacy

Research in the literature shows that minority communities have a high willingness to participate in clinical trials and high self-reported general knowledge about the clinical research process. Yet, according to a recent study conducted by the Center for the Study of Drug Development at the Tufts University School of Medicine, minority patients – most notably those of Black and African descent– are highly underrepresented in clinical trials of new medical interventions. Tufts research also shows that patient referral rates into clinical trials among practicing minority physicians and nurses are very low.

To address the critical need to improve patient diversity in clinical trials, CISCRP – in partnership with ten leading pharmaceutical companies and clinical research service providers – has launched a new consortium that will focus energy and resources on community-based education during the next five years beginning in early 2020. Consortium members include Merck, IQVIA, Biogen, Otsuka, CSL Behring, Janssen, WCG, Boston Scientific, EMD Serono, and Pfizer. Representatives from each member company will participate on a steering committee and will provide staff and resources to support the planning and execution of live educational events in five targeted urban centers annually.

“This centralized approach is vital to bring together the necessary oversight and infrastructure required to engage with communities from around the country,” said Jonathan Jackson, Ph.D., study volunteer and The Center Director of Community Access, Recruitment, and Engagement (CARE) Research Center at the Massachusetts General Hospital, Harvard Medical School.

The Consortium initiative builds on CISCRP’s 18-year experience producing and hosting internationally recognized live educational events – called AWARE-for-ALL programs — throughout the United States and parts of Europe. Each event engages a local planning committee comprised of members of the public, patients, advocacy groups, health care and clinical research professionals, offers educational presentations and discussions, as well as free health screenings and information about local clinical trial activity. The consortium also plans to mobilize a pop-up educational exhibit in targeted urban health centers to generate excitement and awareness in the weeks leading up to each live event.

“We are thrilled to be working with Consortium members on this important and novel initiative,” said Ellyn Getz, Associate Director of Development & Community Engagement at CISCRP. “Support, input and insight from consortium members presents an unprecedented opportunity to have an even greater impact on advancing public and patient clinical research literacy over a 5-year time period with ongoing continuous improvement,” she added.


The Center for Information and Study on Clinical Research Participation (CISCRP) is an internationally recognized 501(c)(3) non-profit organization dedicated to educating, informing and engaging the public

and patients about clinical research. CISCRP is committed to providing services designed to help professionals best engage patients as partners in the clinical research process. Visit .

Contact Information
Joan A. Chambers
Senior Director, Marketing & Outreach

Phone: 617-725-2750 ext. 202


Retention Strategies for Keeping Participants Engaged

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) aims to speed clinical research by removing obstacles that stand in the way of drug development. In pursuit of this mission, the Foundation gathers insights from a wide range of stakeholders and uses these perspectives to enhance clinical trial processes from start to finish. In Applied Clinical Trials’ Eye on Patient Advocacy series, we will share best practices and lessons learned from the field of Parkinson’s research that can be applied to clinical trials across disease states. In our fourth column in this series, we explore retention strategies used in a landmark longitudinal Parkinson’s disease (PD) study.

To complete a study, it is critical to retain study participants. Participant attrition has the potential to interfere with the scientific validity of a study and distort data designed to measure drug efficacy and safety. According to Forte Research:1

  • Eighty-five percent of clinical trials fail to retain enough participants.
  • The average dropout rate across all clinical trials is 30%.

Patient retention is an important element of the Parkinson’s Progression Markers Initiative (PPMI), a landmark, longitudinal, observational study sponsored by The Michael J. Fox Foundation. PPMI ( aims to find reliable and consistent biomarkers for PD progression by studying cohorts of Parkinson’s patients (de novo idiopathic PD and PD-manifesting genetic mutation carriers), populations at risk for PD (non-manifesting genetic mutation carriers and subjects at risk due to REM sleep behavior disorder or hyposmia), and controls without PD.

Participants in PPMI commit to long-term participation, providing biospecimens (e.g., blood, urine, spinal fluid), and undergoing multiple neuroimaging, clinical and behavioral procedures, and assessments over a period of at least five years.

The study launched in 2010, and since then, approximately 1,500 individuals have enrolled. PPMI’s retention rate has consistently held strong, year after year, at about 86%.

To ensure steady participation and to prevent attrition, PPMI weaves together four key tenets of retention, cultivated and refined since study launch: 1) facilitate participation; 2) communicate study progress; 3) express appreciation; and 4) inform participants of study results.

Facilitate participation through travel concierge services, reimbursement, and remote visits. PPMI study leadership prioritized and simplified long-term participation in large part because individuals carrying specific PD-linked genetic mutations live across a wide geographical area. To facilitate volunteers’ continued participation, PPMI cultivated a boutique experience for them and their care partners. Prospective and enrolled PPMI participants are given the option for complimentary roundtrip transportation between their home and appointments at two “super sites” that have the capacity to handle a high volume of study volunteers.

A third-party vendor manages all logistical planning, including participants’ accommodations, meals, and travel to and from study visits. This door-to-door service reflects the value PPMI study leadership puts on participation and participants. For participants who choose not to travel to a super site, travel and hotel expenses are reimbursed through Greenphire/ClinCard. PPMI leadership is always looking for ways to reduce participant burden and is currently exploring the possibility of remote (video and enhanced phone) and home visits.

Communicate study progress through newsletters, update calls, and a centralized webpage. Reminding participants of the bigger picture is a meaningful way to engage them in the collective success of a study. According to a 2017 report by The Center for Information and Study on Clinical Research Participation,2 the number one reason individuals choose to participate in clinical research is to help advance science or the treatment of a disease or condition. Given this initial motivation, updates on study progress and contributions to the field will facilitate continued engagement. In PPMI, study progress is communicated in several ways:

  • PPMI newsletters provide high-level updates on the study (e.g., study enrollment progress, how the data and samples collected are being used for research) as well as interviews or profiles of study participants and/or study staff.
  • PPMI update calls, which are scheduled throughout the year, feature presentations and Q&A sessions with study researchers and study team members.
  • A PPMI participant webpage allows centralized access to digital versions of the participant newsletters and recordings of study update calls.
  • PPMI blog provides regular news about the study, including recent findings that have emerged from the data.

Express appreciation through a thank-you booklet. Letters from members of the Parkinson’s community, researchers, MJFF staff, statisticians, and study coordinators were published in a print and digital booklet to thank and honor volunteers for their participation. Collecting the personal reflections of the many individuals involved in or impacted by PPMI is a meaningful way to empower participants and remind them of the larger cause they are tied to.

Inform participants of study results through newsletters, update calls, and a webpage. The majority of study volunteers (90%) want to receive results from the clinical trial in which they participated.3 Because there is ongoing analysis of PPMI data and continued follow up of participants, study results are shared on a rolling basis. Using familiar channels to communicate study progress is a great way to close the loop with study participants.

Putting it all together: Host an event

PPMI staff and study leadership also show their commitment to the study’s success, and their appreciation for participants, by hosting annual study update luncheons and dinners that incorporate all the tenets of retention. Having an in-person get together gives participants the chance to meet other volunteers and share experiences of living with PD and taking part in PPMI. During these events, local site staff present study progress and provide relevant results from ongoing data analysis. Michael J. Fox Foundation staff also attend and, together, all study stakeholders thank participants for their time and commitment.

Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database ( For up-to-date information on the study, visit

PPMI—a public-private partnership—is funded by The Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck & Co., Meso Scale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics.


  1. Lopienski, Kristina. “Retention in Clinical Trials – Keeping Patients on Protocols.” Forte Research. June 1, 2015.…
  2. The Center for Information and Study on Clinical Research Participation (CISCRP). “2017 Perceptions & Insights Study: Public and Patient Perceptions of Clinical Research.”…
  3. Getz, Kenneth. “Events That Have Shaped Study Participant Protection.” The Gift of Participation: a Guide to Making Informed Decisions about Volunteering for a Clinical Trial, 2nd ed., CISCRP, Center for Information & Study On Clinical Research Participation, 2014, pp. 158–158.

James Gibaldi, MS, Associate Director; and Bernadette Siddiqi, MA, Associate Director; both with The Michael J. Fox Foundation in New York, NY. To contact the MJFF Recruitment and Retention Team, email:

MJFF would like to acknowledge the following individuals for their contribution to the research presented in this case study: Vanessa Arnedo, MPH, Sarah Berk, MPH, Sohini Chowdhury, MA, Tara Hastings, MA, Catherine M. Kopil, PhD, and Alyssa Reimer.

Announcing The Gift of Participation, 3rd edition, the Ultimate Guidebook on Clinical Research Participation

The Gift of Participation, 3rd edition, written by Ken Getz, Founder of CISCRP, is now available. The book is a comprehensive, easy-to-read guide for patients and caregivers seeking information about the clinical research process.

The Center for Information and Study on Clinical Research Participation (CISCRP) is pleased to announce the release of the third edition of The Gift of Participation. Written by CISCRP Founder, Ken Getz, the book is a comprehensive, easy-to-read guide for patients, caregivers and families to navigate the clinical research process. The new edition offers a fresh look at why participation in clinical research matters. The book features important updates on core information and new areas including the role of social and digital media in clinical research, the collection of bio-marker data and generic materials, evolving rules on clinical trial results disclosure, and more.

Clinical trials are essential to public health. Behind every medicine and treatment available are clinical trials and volunteers who sacrificed their time. Author Ken Getz notes, “For the majority of people, the idea of clinical trials is a new and unfamiliar one. Most people first learn of them at the same time they are diagnosed with a serious illness for which no medication is available or adequate. This rush to navigate the unfamiliar terrain of clinical trials is often overwhelming and confusing.”

According to CISCRP’s 2017 Perceptions and Insights Study, a majority of the public, close to 70%, has never or rarely considered clinical studies as an option when discussing treatment or medication options with their doctor. This may come as a result of common myths about clinical research. The nonprofit CISCRP strives to debunk these myths and help patients and their caregivers understand the clinical research process and what it means to be a clinical research participant.

For many patients, clinical trials can be life changing due to the access participants gain to cutting-edge research and expert medical care. Clinical trial participant Meisha Brown was involved in clinical trials from the time she was 8 years old for Burkitt lymphoma. In the book’s foreword she shares, “An opportunity to participate in a clinical trial offered me a beam of hope and gave me a fighting chance when the state of affairs was seemingly hopeless.”

To order a copy of The Gift of Participation, visit CISCRP’s online store at All proceeds are donated to CISCRP and supports the educational initiatives to assist those seeking to learn more about volunteering in clinical trials.

The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP offers free education and outreach to the general public and patient communities. Visit for more information or to support CISCRP’s educational initiatives.

CISCRP Invites Atlanta Community Members to Free Health Event

On Thursday, September 26, CISCRP will host AWARE for All, a free health event, for the Atlanta community. To learn more and reserve your spot for this event visit or call 1-877-MED-HERO (1-877-633-4376).

The Center for Information and Study on Clinical Research Participation (CISCRP) invites the Atlanta community to attend AWARE for All, a free health event on Thursday, September 26, from 5:00 p.m. – 8:00 p.m. EST. CISCRP’s AWARE for All is a program that has been hosted in over 60 communities around the world since 2003. This unique program enables the public to learn about the clinical research process and how it plays into public health.

This will be the first AWARE for All event the nonprofit has held in Georgia. CISCRP’s Associate Director of Development & Community Engagement, Ellyn Getz, notes, “We are excited to bring our internationally-recognized program to the Atlanta community and are thankful for the support we have received from many local organizations. AWARE for All events provide a unique opportunity for the public to interact with professionals in the clinical research field and gather the information they need to make informed decisions about their health.”

CISCRP will be providing free dinner and refreshments. Attendees will have access to several free health screenings including Breast Health, Blood Pressure, Depression, Diabetes, Eating Disorder, Flu Vaccinations, HIV, Memory, Nutrition Counseling, Sickle Cell, Smoking Cessation Counseling, and Vision. Local health advocates and researchers will be in attendance to share their resources and services. There will also be an overview presentation about clinical research and a panel discussion featuring research professionals and study participants.

CISCRP is producing the event in collaboration with Biogen and National Sponsor, Lupus Research Alliance (LRA). The LRA National Director of Advocacy and Programs, Diane Gross, MPH comments, “Lupus Research Alliance is proud to continue our support for an event that aims to improve awareness about clinical research, particularly among minority and underserved communities. This is an important chance for the Atlanta community to come together to address the need for greater education and to recognize those who take part in clinical research studies.”

AWARE for All – Atlanta will be held on Thursday, September 26, 2019 from 5:00 p.m. – 8:00 p.m. EST at the Ivy Community Center, 3850 Stone Road SW Atlanta, GA 30331. Attendance is free, but please reserve your spot today by visiting or by calling toll free 1-877-MED-HERO (1-877-633-4376).

The Center for Information and Study on Clinical Research Participation (CISCRP) is a 501(c)(3) non-profit organization dedicated to engaging the public and patients as partners in the clinical research process. CISCRP provides free education and outreach to the general public and patient communities. Visit for more information or to support CISCRP’s educational initiatives.

Editor’s Note:
Community and research collaborators include: ACRP, Alpha Kappa Alpha Society, Alzheimer’s Association, ARCH, Arthritis Foundation, Biogen, Black Nurses Rock, BrightFocus, Cancer Support Community Atlanta, Clinical Research Atlanta, Cogniciti, Emory Goizueta Alzheimer’s Disease Research Center, Georgia Ovarian Cancer Alliance, HEAL, iResearch Atlanta, the Ivy Community Foundation, the Lupus Research Alliance, Morehouse School of Medicine, Multiple Sclerosis Center of Atlanta (MSCA), and Walgreens.

Plain Language for Health Workshop

Join Behtash Bahador, CISCRP’s Senior Manager of Quality and Compliance and Tufts Alumni, at the Plain Language for Health workshop at Tufts University School of Medicine. Behtash will be participating in a panel discussion on day one of this Writing and Design Workshop for Health Research and Practice for community engagement.

When: March 28 – 29, 2019
Where: Tufts University School of Medicine (Boston, MA)
Link to Register:

More Information About the Program:

The program features experts in health literacy and plain language, interactive peer-learning, and an evening Networking event sponsored by CommunicateHealth. Participants will learn actionable plain language skills and techniques to improve community engagement, trust and transparency, and overall connection with patients, research participants, and the public. It is also an opportunity for people with diverse perspectives, including research teams and participants, librarians, public health professionals, health communicators, community members and others to talk about how to communicate complex health research and practice concepts in ways people can understand. Learn new skills, gain valuable tools, and make lasting connections. For more information visit or email Phil Oettgen, Project Manager,

CISCRP and PRA Health Sciences Collaborate to Provide Clinical Trial Results Summaries to Patients and the Public

The Center for Information and Study on Clinical Research Participation (CISCRP) and PRA Health are pleased to announce that they are collaborating to prepare and deliver Trial Results Summaries to study volunteers. A key focus for both parties is to provide a more positive overall experience for both patients and families throughout the clinical trial process. Keeping patients informed and engaged with meaningful information through this unique collaboration will help achieve that goal.

Trial Results Summaries — also called lay language summaries or plain language summaries — communicate the results of clinical trials in a format and layout that is easy to understand and accessible to patients and the public. Research sponsors have an ethical obligation to provide plain language results summaries. These summaries also help to ensure transparency and reinforce trust and engagement between sponsors, researchers, clinical trial participants, patients and the general public.

Studies show that although the vast majority of clinical trial participants want to know what research professionals have learned from their participation, very few actually do. A recent study, for example, found that more than 90% of study volunteers want to know the general findings of their clinical trial yet only 11% report receiving the results. In another study, research volunteers indicated that the return of trial results is one of the top reasons for deciding to participate.

The return of plain language trial results summaries will soon become mandatory for studies conducted in the European Union (EU). The EU Clinical Trials Regulation (EU) No 536/2014 is expected to come into effect in 2020 and will require sponsors to provide trial results “for laypersons” through the European Medicines Agency (EMA) portal and database. As a result, a growing number of EU-based and global pharmaceutical and biotechnology companies are looking for support from their contract service providers and from CISCRP.
PRA’s medical writers will draft the Trial Results Summaries and implement the company’s quality control processes to ensure the accuracy of both the data and the message. Based on its expertise in health communication, patient engagement and industry best practices developed through nearly a decade of collaboration with research sponsors, CISCRP will ensure the summaries are easy to understand; meet the needs of participants, patients and the public; and are objective and neutral. CISCRP coordinates the review of all summaries through Editorial Panels composed of members of the public as well as patients, patient advocates, and healthcare specialists in the therapeutic area of the study. CISCRP manages production and  into patient languages of the report and facilitates dissemination to participants through investigative sites.

This collaborative effort will ensure the unbiased, non-promotional communication of study results in a systematic and scalable way. Most importantly, this will provide an effective and reliable means of ensuring that trial participants stay informed about what was learned as a result of their participation. PRA Vice President, Medical Writing and Clinical Trial Transparency, Karen Devcich said, “We are delighted to collaborate with CISCRP as part of a cultural transformation towards real patient engagement and to demonstrate genuine commitment to improving the lives of patients.”

“We are very pleased to be collaborating with PRA to enhance the experience and engagement of their patients,” added Jill McNair, CISCRP’s Senior Director, Patient Engagement. “This collaboration also helps to further our mission to make the return of plain language trial result summaries a standard practice adopted by the clinical research community.”

The Center for Information and Study on Clinical Research Participation (CISCRP) is a non-profit organization dedicated to educating the public and patients and to engaging these critical stakeholders as partners in the clinical research process.

The service listed in this post is one example of the many services CISCRP can offer clinical trial sponsors. We are involved in Patient Advisory Boards, Health Communication Consultation and User-Testing through Editorial Panels, Patient and Public Education and Engagement vents and initiatives, free Search Clinical Trials service, and numerous additional services throughout the clinical trial process to certify patient input is incorporated, and that there is consistent engagement with those who volunteer their time to help improve medical treatments.

PRA Health Sciences is a full-service global contract research organization, providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA’s integrated services include data management, statistical analysis, clinical trial management, medical writing and regulatory and drug development consulting. PRA’s global operations span more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over
15,800 employees worldwide. Since 2000, PRA has participated in approximately 3,700 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 75 drugs. To learn more about PRA, please visit


CISCRP at Expanded Access Summit

CISCRP is attending the second annual Expanded Access Summit in Washington D.C. The conference focuses on integrating expanded access into the modern drug development process. Behtash Bahador, our Senior Manager of Quality and Compliance, will be moderating a session on patient agency with the Executive Director of the Let Them Be Little X2 Foundation Jeff Leider and the Founder and President of the Turner Syndrome Global Alliance Kelly Ranallo. CISCRP will also be exhibiting at the forum. Stop by our table to meet Nova Getz, a Research Associate at CISCRP, to learn more about our programs and services.

Haven’t registered but are interested in attending? Register Here and use code: CISCRP300 for a special discount.

CISCRP Launches Virtual Fitness Challenge to Recognize Clinical Trial Volunteers

Appreci-a-thon runs throughout the month of February and accommodates each individual’s personal physical activities.

The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization announces that it has launched a virtual fitness challenge to raise awareness and recognize people who participate in clinical trials. This novel event – dubbed the Medical Hero Appreci-a-thon – encourages patients, professionals and the public to show their support.

A large and growing body of research shows that general public awareness and understanding of the important, courageous and altruistic role of clinical trial participants is low. An estimated 1.8 million people volunteered to participate in clinical trials regulated by the Food and Drug Administration in 2018. Without these volunteers, the development of new medical treatments and the advancement of public health would not occur.

CISCRP invites the public, patients, health and clinical research professionals to “go the distance” and show their support by registering and participating in a fitness challenge that follows a virtual Route 66 race course. Participants can conveniently log any and all forms of physical activity to advance along the virtual route each day. Proceeds from the virtual fitness challenge will support educational programs designed to help patients and their families better navigate the clinical research experience.

Since 2003, CISCRP has been producing educational and awareness-building programs and events nationwide including AWARE-for-ALL and the Medical Heroes 5K run/walk.

“We’ve collaborated with the National Institutes of Health and the private sector to develop a number of awareness building campaigns including ‘Behind Every Medicine’, ‘Medical Heroes in Everyday Places,’ and the ‘MT Pharmacy’ during the past 15 years,” said Ken Getz, CISCRP’s founder. “With the new Medical Hero Appreci-a-thon, CISCRP hopes to attract and raise awareness and active support among a much larger audience.”

The Med Hero Appreci-a-thon challenge officially begins on February 1, 2019 and runs through February 28. CISCRP has produced this event in collaboration with Racery, an organization that designs platforms to power virtual fitness activities. Registration is now open and participants can register at For additional information, call CISCRP at 877-633-4376 or email

Our Virtual Platform Partner: Racery

Bayer and CISCRP Collaborate with Patients and the Public to Redesign the Trial Finder Website

Bayer AG recently partnered with CISCRP and TrialScope to redesign Bayer’s information hub on clinical trials. This online resource allows patients and their families, the public and healthcare providers to navigate through Bayer’s clinical trials and provides comprehensive information for a better understanding of the drug development process. The redesign of the website is part of Bayer’s on-going commitment and work to support patient engagement in clinical research by making it easier for patients to navigate and understand the clinical trials.

The Trial Finder website was redesigned and tested in collaboration with patients and members of the public to make it easier to find and understand information about Bayer’s clinical trials happening around the world, including an overview of the results. The site features videos, frequently asked questions, and other educational content about clinical trials, such as what patients can expect if they participate in the research process.

To ensure that the appropriate perspectives were incorporated throughout the development of the website, CISCRP gathered feedback from patients and members of the public who had previously searched for trials. Their insights, such as how to better display lists in the search tool and the need to provide directly accessible definitions of medical terms, was critically important to ensuring that the website is easy-to-use, and that it provides important information, in a manner that is easy-to-understand.

The website allows people to search and filter Bayer trials based on a number of helpful options. Some examples of these are:

  • the medical condition studied in the trial
  • the locations of trial sites
  • the status of the trial, for example: “recruiting” or “study completed”

Each Bayer trial has a webpage that has been designed to show the information patients find most important, in a way that is easy to read and understand.

CISCRP was delighted to collaborate with Bayer and leverage our many years of expertise to develop patient and public friendly materials for the website relaunch. CISCRP conducted in-depth user-testing, to guarantee that this website included as much patient and public feedback as possible. This project reflects the importance of raising clinical research literacy by jointly transforming current tools and innovating new ones for the benefit of patients and the public.

CISCRP looks forward to continuing our support of Bayer and other organizations that are committed to treating patients as partners in the clinical research process.   

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. The Patient Insights & Engagement team of Bayer is happy to receive feedback from users so that they can continue to enhance the trial finding experience, so if you do have comments, please reach out to


The service listed in this post is one example of the many services CISCRP can offer clinical trial sponsors. We are involved in Patient Advisory Boards, Lay Language Summaries, Editorial Panels, and numerous additional services throughout the clinical trial process to certify patient input is incorporated, and that there is consistent engagement with those who volunteer their time to help improve medical treatments. CISCRP welcomes new projects like this Trial Finder website, to continue to advance ways we can inform and educate individuals participating, or considering participating, in clinical trials.